Portfolio companies
|
Adenium Biotech develops broad-spectrum antibiotics for the treatment of urinary tract infection. |
|||
|
|
|||
|
|
|||
|
Aros Pharma is a biotech company focusing on novel pharmaceuticals targeting unmet needs within pain relief, infectious disease, inflammation, respiratory diseases and immuno-suppressed patients. Projects of interest are in late pre-clinical, phase I or early phase II. Novo A/S board representatives: Stephan Christgau and Bobby Soni |
|||
|
|
|||
|
|
|||
|
C10 Pharma is a research and development company focusing on the development of new antibiotics to combat infections caused by both Gram positive and Gram negative bacteria. At the core of the companys research program is novel chemistry that enables semi-synthetic modifications of part of macrolide molecules previously not available for modifications. Novo A/S board representative: Bobby Soni |
|||
|
|
|||
|
|
|||
|
Concit Pharma identifies and develops innovative drug combinations for treatments of movement disorders and pain. Novo A/S board representative: Bobby Soni |
|||
|
|
|||
|
|
|||
|
Cytoguide is devoted to the development of combined drugs that target receptors on cells in pathological tissues for medical purposes by linking drug candidates and registered drugs with known pharmacological effects to targeting receptor-binding protein partners. The development of receptor-targeted therapeutics will focus on the macrophage specific receptor CD163, the most abundant transport receptor on macrophages. Novo A/S board representative: Henrijette Richter |
|||
|
|
|||
|
|
|||
|
EpiTherapeutics is a drug discovery and development company formed in 2008 based on discoveries at the Biotech Research and Innovation Centre (BRIC) at Copenhagen University. The company develops new drugs with the ability to regulate epigenetic mechanisms. The company’s lead program targets prostate cancer. Novo A/S board representative: Stephan Christgau |
|||
|
|
|||
|
|
|||
|
Inagen is focused on developing novel treatments for intracellular parasitic diseases that include viral, bacterial or protozoan infections. The company is developing therapeutic candidates for viral diseases. The company’s primary candidate is treatment for Cytomegalovirus (CMV). There is a great unmet need for effective and affordable treatment to eradicate this serious disease. Novo A/S board representative: Stephan Christgau |
|||
|
|
|||
|
|
|||
|
MycoTeQ discovers and develops novel natural antibiotics against gram-negative bacteria. The pipeline of the company is based on natural small molecules produced by microfungi. A proprietary compound library representing microfungi from a range of biological niches forms the core of the discovery process. Novo A/S board representative: Henrijette Richter |
|||
|
|
|||
|
|
|||
|
Nanoference Nanoference is focusing on oral and pulmonary delivery of RNAi drugs. Novo A/S board representatives: Henrijette Richter and Bobby Soni |
|||
|
|
|||
|
|
|||
|
Pcovery, Inc. is focusing on structure based drug development against membrane protein drug targets with a broad portfolio of innovative technolgogies, drug targets and chemical products. Pcovery apply biotechnology to improve the way people live. Pcovery creates and commercializes new drugs to treat various human and agricultural diseases. Novo A/S board representative: Stephan Christgau |
|||
|
|
|||
|
|
|||
|
Thrombologic is working to prevent sepsis and multiple organ failure from claiming the lives of intensive care patients in hospitals all over the world. Thanks to a new understanding of the pathogenesis that causes multiple organ failure, they hope to realize our mission in the foreseeable future. They believe sepsis can be treated within the framework of existing therapies, enabling them to take a shorter path when developing a treatment that could save thousands of lives every year. Novo A/S board representative: Stephan Christgau |
|||
|
|
|||